NCT02171806已完成1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (2.5 μg, 10 μg, and 30 μg) of BI 1744 CL for 14 Days in Healthy Male and Female Volunteers (Doubleblind, Randomised, Placebo Controlled [at Each Dose Level] Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 47
- 主要终点
- Number of patients with clinically significant changes in physical examination
研究概览
简要总结
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1744 CL
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female based upon a complete medical history, including the physical examination, regarding vital signs (blood pressure (BP), pulse rate (PR)), 12-lead ECG measurement, and clinical laboratory tests. There is no finding deviating from normal and of clinical relevance. There is no evidence of a clinically relevant concomitant disease.
- •Age ≥21 and ≤50 years
- •BMI ≥18.5 and <30 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR, and ECG measurements) deviating from normal and of clinical relevance
- •Evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients) as judged clinically relevant by the investigator
- •Intake of drugs with a long half-life (>24 hours) within at least 1 month or less than 10 half-lives of the respective drug prior to randomisation
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to randomisation
- •Participation in another trial with an investigational drug within 2 months prior to randomisation
- •Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
- •Inability to refrain from smoking on trial days as judged by the investigator
- •Alcohol abuse (more than 60 g alcohol a day)
- •Drug abuse
- •Blood donation (more than 100 mL blood within 4 weeks prior to randomisation or during the trial)
- •Excessive physical activities within 1 week prior to randomisation or during the trial
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of the study centre
- •The following exclusion criteria are specific for this study due to the known class side effect profile of ß2-mimetics:
- •Asthma or history of pulmonary hyperreactivity
- •Hyperthyrosis
- •Allergic rhinitis in need of treatment
- •Clinically relevant cardiac arrhythmia
- •Paroxysmal tachycardia (>100 beats per minute).
- •For female subjects:
- •Pregnancy
- •Positive pregnancy test
- •No adequate contraception e.g. oral contraception, sterilisation, IUD (intrauterine device). Females who are not surgically sterile will be asked to additionally use barrier contraception methods (e.g. condoms) prior to administration of study medication, during the study and at least 2 months after release from the study.
- •Inability to maintain this adequate contraception during the whole study period
- •Lactation period
研究组 & 干预措施
BI 1744 CL multiple rising doses
Experimental
干预措施: BI 1744 CL (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
BI 1744 CL medium dose, females
Experimental
干预措施: BI 1744 CL (Drug)
结局指标
主要结局
Number of patients with clinically significant changes in physical examination
时间窗: Baseline, day 32 (end-of-study examination)
Number of patients with clinically significant changes in vital signs
时间窗: Baseline, up to day 32
Number of patients with clinically significant changes in 12-lead ECG (Electrocardiogram)
时间窗: Baseline, up to day 32
Number of patients with abnormal changes in laboratory tests
时间窗: Baseline, up to day 32
Changes in airway resistance (Raw) measured by body plethysmography
时间窗: Baseline, up to day 32
Changes in tremormetry parameters
时间窗: Baseline, up to day 32
Number of patients with adverse events
时间窗: Up to day 32
Assessment of tolerability by the investigator on a 4-point scale
时间窗: Day 32 (end-of-study examination)
次要结局
- Cmax (maximum concentration of the analyte in plasma)(Up to 408 hours after drug administration)
- tmax (time from dosing to maximum concentration)(Up to 408 hours after drug administration)
- AUC (area under the concentration-time curve of the analyte in plasma at different time points)(Up to 408 hours after drug administration)
- Aet1-t2(amount of analyte that is eliminated in urine from the time point t1 to time point t2)(Up to 384 hours after drug administration)
- fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)(Up to 384 hours after drug administration)
- %AUCtz-∞ (the percentage of the AUC 0-∞ that is obtained by extrapolation)(Up to 408 hours after drug administration)
- λz (terminal rate constant of the analyte in plasma)(Up to 408 hours after drug administration)
- t½ (terminal half-life of the analyte in plasma)(Up to 408 hours after drug administration)
- MRTih (mean residence time of the analyte in the body after inhalation)(Up to 408 hours after drug administration)
- CL/F (apparent clearance of the analyte in the plasma after extravascular administration)(Up to 408 hours after drug administration)
- Vz/F (apparent volume of distribution of the analyte during the terminal phase λz following an extravascular dose)(Up to 408 hours after drug administration)
- CLR,t1-t2 (renal clearance of the analyte in plasma from the time point t1 until the time point t2)(Up to 408 hours after drug administration)
- RA,Cmax,14 based on Cmax (Accumulation ratio of the analyte in plasma after multiple dose administration over a uniform dosing interval τ)(Up to 408 hours after drug administration)
- RA,AUC,14 based on AUC0-τ(Up to 408 hours after drug administration)
- Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(Up to 408 hours after drug administration)
- Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)(Up to 408 hours after drug administration)
- Linearity Index (LI)(Up to 408 hours after drug administration)
研究者
相似试验
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male VolunteersHealthyNCT02259959Boehringer Ingelheim36
已完成
1 期
A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female VolunteersHealthyNCT02171780Boehringer Ingelheim122
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male SubjectsHealthyNCT02209844Boehringer Ingelheim72
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT02211963Boehringer Ingelheim48
终止
1 期
Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male SubjectsHealthyNCT02172131Boehringer Ingelheim64